GMP and cGMP are not the same thing, even though the terms are often used interchangeably. GMP stands for Good Manufacturing Practice and refers to a defined set of quality standards. The “c” in cGMP stands for “current,” signaling that manufacturers must apply the most up-to-date methods and technologies available, not just meet a fixed minimum standard written years ago. The sections below unpack what that distinction means in practice, how it plays out across different regions and product types, and what your company needs to do to stay compliant.
Why does the ‘c’ in cGMP actually change anything?
The “c” in cGMP transforms a static checklist into a living obligation. While GMP defines baseline requirements for manufacturing quality, cGMP requires manufacturers to continuously adopt current best practices, updated equipment, and the latest scientific understanding. A facility that met the standard five years ago may no longer be compliant if better methods are now widely available and expected by regulators.
This distinction matters because regulatory agencies like the US Food and Drug Administration interpret cGMP as a dynamic standard. The regulations themselves may not change every year, but the agency’s expectations evolve alongside advances in manufacturing science, process analytical technology, and quality risk management. A manufacturer that relies on outdated practices risks enforcement action even if those practices were once acceptable.
In short, the “c” shifts the burden onto manufacturers to stay informed and proactive rather than simply passing an audit against a fixed rulebook.
Are GMP and cGMP the same in the EU and the US?
GMP and cGMP refer to the same underlying concept but are governed by different regulatory frameworks depending on the region. The US FDA enforces cGMP through Title 21 of the Code of Federal Regulations. The European Union applies GMP requirements through EU Directive 2003/94/EC, the EudraLex Volume 4 guidelines, and relevant ICH guidance. Both frameworks share core principles but differ in structure, terminology, and specific requirements.
One practical difference is that the EU framework tends to be more prescriptive in certain areas, particularly around documentation and Qualified Person responsibilities, while the FDA’s cGMP regulations are often described as more principles-based, leaving manufacturers greater flexibility in how they demonstrate compliance. However, this flexibility comes with the expectation that manufacturers will apply current scientific knowledge to justify their approach.
For companies operating in both markets, harmonization through ICH guidelines helps bridge many of these differences, but a dual-market strategy still requires careful mapping of requirements to ensure each submission and facility meets the specific expectations of each authority. Learn more about our regulatory and quality services to see how we support clients navigating multi-market compliance.
What does cGMP compliance require in practice?
cGMP compliance requires manufacturers to maintain robust quality systems, validated processes, controlled facilities, and comprehensive documentation throughout the entire product lifecycle. It is not limited to the manufacturing floor. It extends to raw material sourcing, laboratory testing, equipment qualification, personnel training, change control, and deviation management.
Key practical requirements typically include:
- Process validation: Demonstrating that manufacturing processes consistently produce a product meeting its specifications
- Equipment qualification: Ensuring all equipment is installed, operated, and performs as intended
- Documentation control: Maintaining complete, accurate, and traceable records for every batch and every critical decision
- Personnel training: Ensuring all staff involved in manufacturing and quality functions are trained and competent for their roles
- Quality risk management: Proactively identifying, assessing, and controlling risks to product quality
- Change control: Evaluating and documenting any changes to processes, materials, or equipment before implementation
- Deviation and CAPA management: Investigating departures from procedures and implementing corrective and preventive actions
The “current” element means that expectations around areas like data integrity, computerized system validation, and contamination control have grown significantly more demanding in recent years and continue to evolve.
Which products must follow GMP versus cGMP rules?
The specific framework that applies depends on the product type and the market where it will be sold. In the US, cGMP applies to finished pharmaceuticals, active pharmaceutical ingredients, biological products, and medical devices. In the EU, GMP requirements apply to medicinal products, investigational medicinal products, and active substances, while medical devices are governed by separate quality management standards under the MDR and IVDR, typically aligned with ISO 13485.
For biologics, vaccines, and advanced therapy medicinal products, GMP requirements are often more stringent than those applied to conventional small-molecule drugs, reflecting the additional complexity and variability inherent in biological manufacturing. Drug-device combination products add another layer of complexity because they may need to satisfy both pharmaceutical GMP and medical device quality system requirements simultaneously.
Understanding which framework applies to your product from the earliest development stages is essential. Applying the wrong standard or failing to anticipate dual requirements can create costly delays at the point of regulatory submission or inspection. If you are unsure which requirements apply to your product, get in touch with our team for tailored guidance.
What happens if a company fails GMP or cGMP compliance?
Failure to meet GMP or cGMP requirements can result in serious regulatory and commercial consequences, ranging from warning letters and import alerts to product recalls, facility shutdowns, and criminal prosecution in the most severe cases. Regulators treat manufacturing quality failures as a direct risk to patient safety, and enforcement reflects that priority.
In the EU, a Qualified Person can refuse to certify a batch if GMP compliance is in question, which immediately blocks that product from reaching the market. The European Medicines Agency and national competent authorities can also suspend or revoke manufacturing authorizations following inspections that reveal systemic deficiencies.
In the US, FDA warning letters are publicly posted and can trigger downstream consequences such as supply chain disruptions, loss of partner confidence, and investor concern. Consent decrees, which are legally binding agreements requiring corrective action under judicial oversight, represent one of the most operationally disruptive outcomes a manufacturer can face.
Beyond formal enforcement, non-compliance can damage a company’s reputation with contract partners, delay product approvals, and create significant remediation costs that far exceed the investment required to maintain compliance in the first place.
How should a company stay current with evolving cGMP expectations?
Staying current with cGMP expectations requires a combination of continuous monitoring, internal training, and proactive quality system management. Regulatory guidance evolves through new ICH guidelines, FDA draft guidances, EMA reflection papers, and inspection trend reports, all of which signal where expectations are heading before formal regulations are updated.
Practical steps companies can take include:
- Subscribing to regulatory agency updates and monitoring published inspection observations and warning letters for trend signals
- Participating in industry associations and working groups that engage directly with regulators on emerging standards
- Scheduling periodic internal audits and gap assessments against current guidance rather than only preparing for external inspections
- Investing in ongoing training programs that reflect the latest expectations, particularly in areas like data integrity and computerized systems
- Engaging with regulatory affairs and quality consultants who maintain active knowledge of current regulatory thinking across multiple markets
The companies that manage cGMP compliance most effectively treat it as a continuous improvement discipline rather than a periodic compliance exercise. Building a quality culture where teams proactively identify and address gaps is far more sustainable than reacting to inspection findings.
How Starodub supports your GMP compliance strategy
Navigating the difference between GMP and cGMP requirements across multiple markets is exactly the kind of challenge we help clients resolve every day. At Starodub, we work with biopharmaceutical and medical device companies to build and maintain compliance programs that reflect current regulatory expectations, not just minimum standards. Find out more about who we are and the experience we bring to every engagement.
Our support covers the full range of GMP compliance needs, including:
- Gap assessments against current EU GMP and FDA cGMP requirements for your product type and manufacturing processes
- Regulatory strategy development for small molecules, biologics, vaccines, and combination products across EU and US markets
- Support for GMP-related sections of regulatory submissions, including CMC documentation and manufacturing dossiers
- Guidance on quality system alignment with GxP, ISO 13485, and ICH Q10 principles
- Operational improvement support through our Quality, Compliance and Operational Improvements division, led by Lean Six Sigma Master Black Belts with over 25 years of pharmaceutical industry experience
We bring deep technical expertise across regulatory affairs and quality, combined with the efficiency of a lean team that offers clear communication and a single point of contact. If you want to make sure your GMP compliance approach reflects what regulators expect in 2026 and beyond, get in touch with us to discuss how we can help.
Related Articles
- How to Write a Clinical Evaluation Report (CER) Under MDR
- What is the difference between ICH and FDA guidelines?
- What is the difference between FDA and EMA approval?
- What are the benefits of ISO 13485 certification?
- What is medical device regulation?
This content was generated with the help of AI — it may contain mistakes
